Fluid Biopsy Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Indication By Type, By Region & Competition, 2021-2031F

The Global Fluid Biopsy Market is projected to grow from USD 11.92 Billion in 2025 to USD 23.82 Billion by 2031, achieving a compound annual growth rate (CAGR) of 12.23%. This market, also known as liquid biopsy, encompasses diagnostic technologies that analyze biological fluids like blood or urine to detect tumor-derived markers, including circulating tumor cells and DNA. Key drivers for this market include the clinical demand for minimally invasive alternatives to surgical tissue extraction and the crucial requirement for repeated sampling to monitor disease progression. These capabilities enable clinicians to acquire real-time genomic data and adjust therapeutic plans without exposing patients to the risks and recovery periods associated with conventional solid tissue biopsies.

The expansion of this sector is further propelled by the increasing global incidence of cancer, necessitating scalable and efficient diagnostic solutions; for instance, the American Cancer Society anticipates approximately 2,041,910 new cancer cases in the United States in 2025. Despite this clear demand, market growth is significantly challenged by inconsistencies in reimbursement coverage and payer policies, which establish financial barriers for healthcare providers and limit widespread patient access to these crucial diagnostic tests.

Market Driver

The Global Fluid Biopsy Market is considerably advanced by the rising adoption of precision medicine and companion diagnostics, as healthcare providers increasingly utilize blood-based tests to guide targeted therapy selection. This involves integrating circulating tumor DNA analysis into routine clinical workflows, enabling precise patient stratification without invasive tissue biopsies. The escalating demand for these diagnostics is evident in industry operational metrics; for example, Natera reported processing approximately 528,200 oncology tests in 2024, marking a substantial 54.9% increase over the previous year, underscoring liquid biopsy's vital role in detecting minimal residual disease and optimizing treatment.

Concurrently, a significant surge in both public and private funding is fueling the research and development efforts essential for enhancing assay sensitivity and commercializing novel screening modalities. This robust financial backing empowers diagnostic companies to conduct pivotal clinical trials and scale operations to meet global demand; for instance, Geneoscopy, Inc., secured $105 million in Series C funding to support the commercial launch of its non-invasive colorectal cancer screening test. Further highlighting the sector's financial health, Guardant Health's total revenue for 2024 reached $739 million, reflecting a 31% increase driven by expanding clinical test volumes.

Market Challenge

Inconsistent reimbursement coverage and payer policies directly impede the growth of the Global Fluid Biopsy Market by introducing substantial financial uncertainty for healthcare providers and commercial laboratories. Despite the clear clinical advantages of liquid biopsy, the high costs associated with next-generation sequencing and genomic analysis necessitate strong insurance support. When commercial payers categorize these diagnostic tests as investigational or restrict coverage to limited clinical indications, healthcare facilities face potential claim denials and non-payment, which deters the widespread adoption of fluid biopsy protocols in routine practice, prompting reliance on traditional, invasive tissue sampling methods that are more reliably reimbursed.

Moreover, this disparity in payer policies curtails market expansion by restricting patient access based on geographical location and insurance type rather than clinical necessity. Without standardized coverage mandates, patients frequently encounter prohibitive out-of-pocket expenses, leading to declined testing and a reduction in potential market volume. The gravity of this obstacle is underscored by recent policy data from the American Cancer Society Cancer Action Network, which noted that as of June 2025, only 18 states had enacted legislation mandating coverage for comprehensive biomarker testing by state-regulated health plans, thereby fragmenting the reimbursement landscape and hindering broader market penetration and scalability of diagnostic services.

Market Trends

The emergence of Multi-Cancer Early Detection (MCED) tests is fundamentally transforming the market by shifting diagnostics from single-organ screening to simultaneous pan-cancer analysis. Unlike conventional methods that examine symptomatic patients, these assays leverage methylation patterns and circulating cell-free DNA to screen asymptomatic populations for numerous malignancies through a single blood draw. This capability effectively addresses the clinical gap for cancers lacking standard screening protocols, thereby significantly expanding the eligible patient population. The commercial momentum of this segment is reflected in recent financial performance, with GRAIL, Inc., reporting its Galleri test revenue reaching $25.4 million in the third quarter of 2024, a 52% increase year-over-year.

Simultaneously, the market is undergoing a crucial expansion into non-oncology applications, particularly within neurology and organ transplant monitoring. Developers are increasingly validating blood-based biomarkers to detect neurodegenerative conditions, such as Alzheimer's disease, and to evaluate allograft health, thereby extending liquid biopsy beyond its traditional oncology focus. This diversification enables manufacturers to mitigate the cyclical risks associated with the cancer diagnostics sector and capitalize on the growing demand for non-invasive neurological assessments, as exemplified by Quanterix Corporation's total revenue of $35.7 million in Q3 2024, largely driven by the acceleration of its neurology-focused diagnostic services.

Key Market Players

• Bio-Rad Laboratories
• Guardant Health Inc.
• Illumina, Inc.
• Qiagen NV
• Laboratory Corporation of America Holdings
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific Inc.
• Johnson & Johnso
• Biocept Inc.
• Bio-Rad Laboratories, Inc.

Report Scope

In this report, the Global Fluid Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fluid Biopsy Market, By Indication

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Other

Fluid Biopsy Market, By Type

• Circulating Tumor Cells
• Circulating Tumor DNA
• Cell-free DNA

Fluid Biopsy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fluid Biopsy Market.

Available Customizations:

Global Fluid Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).